Anonymous GLP-1 expert 'Cremieux' on the drug's expanding use cases — sleep apnea, cancer, ADHD — and the risks of gray market access

Summary

GLP-1 drugs continue expanding well beyond their original diabetes mandate, with the pace of new indications accelerating sharply. At the ongoing American Diabetes Association conference, Amgen unveiled a once-monthly injectable formulation, replacing the current once-weekly standard, while Eli Lilly presented a combination therapy with an inhibitor called Bimagrumab that preserves muscle mass during treatment. Tirzepatide received FDA approval for sleep apnea in December 2024, osteoarthritis indications are described as incoming, and early research suggests potential benefit across obesity-related and hematological cancers, though the mechanism for blood cancers remains unexplained.

The analyst known as Cremieux attributes most of GLP-1's broad therapeutic reach to the sheer systemic damage obesity inflicts, rather than any single pharmacological property of the drugs. Cardiovascular benefits — specifically reductions in major adverse cardiac events — appear almost immediately after initiation and independent of weight loss, suggesting a direct drug mechanism. The same pattern holds for chronic kidney disease.

A growing gray-market ecosystem poses the most visible risk. Cremieux published a guide to sourcing compounded semaglutide from Chinese manufacturers, charging $8 per reader, and claims the guide has driven at least 12,000 pounds of self-reported weight loss across several thousand users. The supply chain involves ordering raw peptide from Chinese factories, testing for purity — results cited at 99.9% — and self-administering without a prescription. The FDA currently tolerates this under a research-chemicals exemption, but enforcement remains essentially absent at ports of entry.

Misuse among people who do not meet clinical thresholds is the clearest documented downside. Cremieux describes encountering dozens of women in the 120–130 lb range who have dropped to approximately 100 lbs, reporting visible aging and muscle loss consistent with lean-mass catabolism rather than fat reduction. A separate and emerging off-label use is microdosing for ADHD symptom management, where users report that suppressing food-related cognitive noise improves focus without meaningful weight loss.

Novo Nordisk's aborted partnership with Hims & Hers is read as a deliberate trap rather than a genuine distribution deal. The allegation, described as unproven pending litigation, is that Hims was selling materially more product than Novo supplied — the framing offered is that if Novo provided one million doses of Wegovy, Hims may have been shipping 1.2 million. The mechanism would be either in-house compounding or Chinese sourcing. Cremieux views Hims's general advocacy for broader access and alternative dosing tiers as legitimate and consumer-beneficial.

A significant near-term access catalyst involves a Novo Nordisk patent lapse — the company failed to pay a roughly $250 fee, then missed the late-payment window of an additional $200, allowing the patent to lapse entirely. That opens the door to the FDA-CMS Section 804 importation program, which permits individual US states to import generic drugs produced in Canada. Generic Ozempic is expected in Canada in 2026, and if states like Florida operationalize Section 804, the analyst projects retail-equivalent pricing of approximately $5 per week for semaglutide in the US — a price point he argues could meaningfully compress the chronic disease and obesity burden at a population level.

On NIH funding, Cremieux declines to detail specific expectations but signals confidence that current cuts are not the final policy posture, pointing to the administration's hiring freeze and Senate confirmation backlog as temporary constraints. He argues public R&D funding needs to increase in both total volume and allocation quality, noting that biotech as an asset class has historically underperformed even with prior funding levels.